Adam Veness Sells 3,833 Shares of Dianthus Therapeutics (NASDAQ:DNTH) Stock

Posted by George Bondi on Aug 11th, 2026

Dianthus Therapeutics, Inc. (NASDAQ:DNTH – Get Free Report) SVP Adam Veness sold 3,833 shares of Dianthus Therapeutics stock in a transaction on Friday, August 7th. The stock was sold at an average price of $110.70, for a total value of $424,313.10. Following the transaction, the senior vice president owned 3,833 shares in the company, valued at approximately $424,313.10. This represents a 50.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Dianthus Therapeutics Price Performance

Shares of DNTH traded down $3.31 during mid-day trading on Tuesday, reaching $108.49. The stock had a trading volume of 777,875 shares, compared to its average volume of 972,407. Dianthus Therapeutics, Inc. has a 52-week low of $19.00 and a 52-week high of $114.55. The firm has a market cap of $5.93 billion, a price-to-earnings ratio of -26.14 and a beta of 1.22. The business’s fifty day moving average is $95.17 and its 200 day moving average is $81.36.

Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) last posted its earnings results on Tuesday, August 4th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.05). Dianthus Therapeutics had a negative net margin of 10,096.95% and a negative return on equity of 22.53%. The firm had revenue of $0.76 million during the quarter, compared to analyst estimates of $0.30 million. As a group, sell-side analysts anticipate that Dianthus Therapeutics, Inc. will post -3.83 EPS for the current fiscal year.

Hedge Funds Weigh In On Dianthus Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. raised its position in Dianthus Therapeutics by 24.7% in the fourth quarter. Vanguard Group Inc. now owns 2,048,452 shares of the company’s stock valued at $84,417,000 after purchasing an additional 406,254 shares during the period. UBS Group AG grew its stake in shares of Dianthus Therapeutics by 342.6% in the fourth quarter. UBS Group AG now owns 606,620 shares of the company’s stock valued at $24,999,000 after buying an additional 469,547 shares in the last quarter. BNP Paribas Financial Markets grew its stake in shares of Dianthus Therapeutics by 1,275.3% in the fourth quarter. BNP Paribas Financial Markets now owns 475,749 shares of the company’s stock valued at $19,606,000 after buying an additional 441,156 shares in the last quarter. SummitTX Capital L.P. raised its holdings in shares of Dianthus Therapeutics by 13.8% in the 1st quarter. SummitTX Capital L.P. now owns 100,044 shares of the company’s stock valued at $8,396,000 after buying an additional 12,118 shares during the period. Finally, California State Teachers Retirement System raised its holdings in shares of Dianthus Therapeutics by 155.5% in the 1st quarter. California State Teachers Retirement System now owns 40,584 shares of the company’s stock valued at $3,406,000 after buying an additional 24,697 shares during the period. Hedge funds and other institutional investors own 47.53% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on DNTH shares. Wedbush increased their price objective on Dianthus Therapeutics from $105.00 to $122.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 5th. Raymond James Financial restated a “strong-buy” rating and issued a $131.00 target price on shares of Dianthus Therapeutics in a research report on Wednesday, August 5th. HC Wainwright upped their price target on Dianthus Therapeutics from $130.00 to $158.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Wall Street Zen upgraded Dianthus Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Finally, Wolfe Research reissued an “outperform” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $124.27.

Check Out Our Latest Analysis on DNTH

About Dianthus Therapeutics

(Get Free Report)

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.